CEL-SCI Corp (CVM) Stock AnalysisCVMStock AnalysisCEL-SCI Corp

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CEL-SCI Corp (CVM) is a good buy right now due to its recent price increase of 34.48% over the last 20 days, and the RSI of 55.76 indicates that the stock is not overbought. Additionally, the stock is currently priced at $1.56, which is significantly below its 200-day simple moving average of $3.455, suggesting potential for upward movement. However, investors should be cautious of the company's ongoing losses, with a net income of -$5,466,751 in Q1 2026, which poses a risk to its financial stability.

1 analysts cover CVM: 0 rate it Buy, 1 Hold and 0 Sell.